Literature DB >> 14504661

Allopurinol inhibits CXC chemokine expression and leukocyte adhesion in endotoxemic liver injury.

L Xiang1, D Klintman, H Thorlacius.   

Abstract

OBJECTIVE: Leukocyte activation and recruitment are rate limiting steps in endotoxemic liver injury. We investigated the effect of allopurinol on the expression of CXC chemokines and leukocyte-endothelium interactions, microvascular perfusion failure, and cellular injury and apoptosis in endotoxemic liver injury.
MATERIALS AND METHODS: Mice were treated with allopurinol prior to challenge with lipopolysaccharide (LPS) + D-Galactosamine (Gal). Intravital microscopy of the liver microcirculation and analysis of liver enzymes were conducted 6 h later.
RESULTS: We observed that allopurinol pre-treatment reduced the number of firmly adherent leukocytes by more than 57% in postsinusoidal venules of endotoxemic mice. Indeed, endotoxin-induced liver injury enzymes were decreased by 76% and sinusoidal perfusion failure was reversed in mice pre-treated with allopurinol. Moreover, administration of allopurinol reduced LPS-induced hepatocyte apoptosis by 56%. Notably, it was found that allopurinol significantly decreased the levels of CXC chemokines (more than 83% reduction) in livers of endotoxemic mice.
CONCLUSIONS: This study shows that allopurinol markedly protects against endotoxemic liver injury and indicates that reactive oxygen species (ROS) mediate synthesis of CXC chemokines and leukocyte adhesion in the liver in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504661     DOI: 10.1007/s00011-003-1184-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

1.  Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats.

Authors:  Ulvi Demirel; Mehmet Yalniz; Cem Aygün; Cemal Orhan; Mehmet Tuzcu; Kazim Sahin; Ibrahim Hanifi Ozercan; Ibrahim Halil Bahçecioğlu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

2.  The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2011-08-11       Impact factor: 17.425

3.  Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}.

Authors:  Sophie Gibbings; Nancy D Elkins; Hillary Fitzgerald; Janice Tiao; Mari E Weyman; Gayle Shibao; Mehdi A Fini; Richard M Wright
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

4.  Protective effect of Gö6976, a PKD inhibitor, on LPS/D: -GalN-induced acute liver injury in mice.

Authors:  G J Duan; J Zhu; C Y Xu; J Y Wan; L Zhang; X D Ge; L M Liu; Y S Liu
Journal:  Inflamm Res       Date:  2010-11-10       Impact factor: 4.575

Review 5.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

6.  XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.

Authors:  Mahendra Damarla; Laura F Johnston; Gigi Liu; Li Gao; Lan Wang; Lidenys Varela; Todd M Kolb; Bo S Kim; Rachel L Damico; Paul M Hassoun
Journal:  Physiol Rep       Date:  2017-08

7.  Xanthine oxidase inhibitors and sepsis.

Authors:  Maria Fátima de Paula Ramos; Alceni do Carmo Morais Monteiro de Barros; Clara Versolato Razvickas; Fernanda T Borges; Nestor Schor
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.